Polypharmacy has undesirable consequences, such as increased risk of potentially inappropriate medication, misuse of doses, either by excess or by default of necessary treatments, nonadherence and increased risk of interactions and adverse drug reactions. Multimorbidity is associated with polypharmacy, defined as the simultaneous consumption of five or more drugs. Multimorbidity affects 81.5% of people older than 85 years, 62% of those 65–74 years old and 50% of those younger than 65 years old. It is estimated that the average number of chronic conditions in those over 75 years is 3.2, while that for the young seniors (65–74 years) is 2.8. Most studies define multimorbidity as the concurrent presence of two or more, or three or more chronic diseases the latter definition is more suitable for the identification of patients with complex health needs. Population aging has led multimorbidity to be becoming increasingly prevalent in the adult population of most Western European countries. Funders had no role in study design or in the decision to submit the report for publication.Ĭompeting interests: The authors have declared that no competing interests exist. The main researchers of the project will be contacted (Alexandra Prados-Torres at Daniel Prados-Torres at and Isabel del Cura at However, each new project based on these data must be previously submitted to CEICA for approval.įunding: This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD16/0001/0006, RD16/0001/0005 and RD16/0001/0004), and the European Regional Development Fund (“A way to build Europe”). The data are part of the MULTIPAP study and can be requested by contacting the Aragon Ethics Committee at the email address for the request of data you can also contact the Primary Care Management of Madrid at the email address and by contacting the Technical Direction of Teaching and Research at the email address The MULTIPAP Group may establish future collaborations with other groups based on the same data. The data contains sensitive clinical information about the patient, so there are ethical and legal restrictions to sharing the data set. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Regarding data exchange, the Aragon Ethics Committee approved this research without considering the option of data sharing.
Received: JanuAccepted: JPublished: June 24, 2020Ĭopyright: © 2020 Lozano-Hernández et al.
PLoS ONE 15(6):Įditor: Delphine De Smedt, Universiteit Gent, BELGIUM (2020) Social support, social context and nonadherence to treatment in young senior patients with multimorbidity and polypharmacy followed-up in primary care. Citation: Lozano-Hernández CM, López-Rodríguez JA, Leiva-Fernández F, Calderón-Larrañaga A, Barrio-Cortes J, Gimeno-Feliu LA, et al.
0 kommentar(er)
